Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 19 June 1998:
Vol. 280. no. 5371, pp. 1871 - 1873
DOI: 10.1126/science.280.5371.1871
Prev | Table of Contents | Next

Viewpoint

HIV Treatment Failure: Testing for HIV Resistance in Clinical Practice

Luc Perrin, Amalio Telenti

Perrin and Talenti discuss how to evaluate antiretroviral therapy for AIDS. Their examination of data from the Swiss HIV cohort study suggest that failure or success is more complicated than analysis of virus replication. These observations have an impact on discussions of the relevance of HIV resistance testing to clinical practice.

The authors are at the Laboratory of Virology, Division of Infectious Diseases, Geneva University Hospital, 1211 Geneva 14, and Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death by Triggering Endoplasmic Reticulum Stress.
P. Pyrko, A. Kardosh, W. Wang, W. Xiong, A. H. Schonthal, and T. C. Chen (2007)
Cancer Res. 67, 10920-10928
   Abstract »    Full Text »    PDF »
Computational methods for the design of effective therapies against drug resistant HIV strains.
N. Beerenwinkel, T. Sing, T. Lengauer, J. Rahnenfuhrer, K. Roomp, I. Savenkov, R. Fischer, D. Hoffmann, J. Selbig, K. Korn, et al. (2005)
Bioinformatics 21, 3943-3950
   Abstract »    Full Text »    PDF »
Health and economic benefits of an accelerated program of research to combat global infectious diseases.
Global IDEA Scientific Advisory Committee (2004)
Can. Med. Assoc. J. 171, 1203-1208
   Full Text »    PDF »
Novel Enzyme-Linked Minisequence Assay for Genotypic Analysis of Human Immunodeficiency Virus Type 1 Drug Resistance.
W. Sugiura, K. Shimada, M. Matsuda, T. Chiba, L. Myint, A. Okano, and K. Yamada (2003)
J. Clin. Microbiol. 41, 4971-4979
   Abstract »    Full Text »    PDF »
Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes.
N. Beerenwinkel, M. Daumer, M. Oette, K. Korn, D. Hoffmann, R. Kaiser, T. Lengauer, J. Selbig, and H. Walter (2003)
Nucleic Acids Res. 31, 3850-3855
   Abstract »    Full Text »    PDF »
Discordant Outcomes following Failure of Antiretroviral Therapy Are Associated with Substantial Differences in Human Immunodeficiency Virus-Specific Cellular Immunity.
D. A. Price, G. Scullard, A. Oxenius, R. Braganza, S. A. Beddows, S. Kazmi, J. R. Clarke, G. E. Johnson, J. N. Weber, and R. E. Phillips (2003)
J. Virol. 77, 6041-6049
   Abstract »    Full Text »    PDF »
Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naive and Pretreated Patients.
O. Gallego, C. de Mendoza, A. Corral, and V. Soriano (2003)
J. Clin. Microbiol. 41, 1245-1247
   Abstract »    Full Text »    PDF »
Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients.
S. Paolucci, F. Baldanti, M. Zavattoni, G. Comolli, N. Labo, S. Menzo, M. Clementi, and G. Gerna (2003)
J. Antimicrob. Chemother. 51, 135-139
   Abstract »    Full Text »    PDF »
Actinomycin D Induces High-Level Resistance to Thymidine Analogs in Replication of Human Immunodeficiency Virus Type 1 by Interfering with Host Cell Thymidine Kinase Expression.
T. Imamichi, M. A. Murphy, J. W. Adelsberger, J. Yang, C. M. Watkins, S. C. Berg, M. W. Baseler, R. A. Lempicki, J. Guo, J. G. Levin, et al. (2002)
J. Virol. 77, 1011-1020
   Abstract »    Full Text »    PDF »
Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma.
S. Pati, C. B. Pelser, J. Dufraine, J. L. Bryant, M. S. Reitz Jr, and F. F. Weichold (2002)
Blood 99, 3771-3779
   Abstract »    Full Text »    PDF »
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.
A. Trkola, S. E. Kuhmann, J. M. Strizki, E. Maxwell, T. Ketas, T. Morgan, P. Pugach, S. Xu, L. Wojcik, J. Tagat, et al. (2002)
PNAS 99, 395-400
   Abstract »    Full Text »    PDF »
Differential Effects of HIV-1 Protease Inhibitors on Dendritic Cell Immunophenotype and Function.
A. Gruber, J. C. Wheat, K. L. Kuhen, D. J. Looney, and F. Wong-Staal (2001)
J. Biol. Chem. 276, 47840-47843
   Abstract »    Full Text »    PDF »
Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 Protein.
S. Peters, M. Munoz, S. Yerly, V. Sanchez-Merino, C. Lopez-Galindez, L. Perrin, B. Larder, D. Cmarko, S. Fakan, P. Meylan, et al. (2001)
J. Virol. 75, 9644-9653
   Abstract »    Full Text »    PDF »
Individual Contributions of Mutant Protease and Reverse Transcriptase to Viral Infectivity, Replication, and Protein Maturation of Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1.
G. Bleiber, M. Munoz, A. Ciuffi, P. Meylan, and A. Telenti (2001)
J. Virol. 75, 3291-3300
   Abstract »    Full Text »
Mature Dendritic Cells Infected with Canarypox Virus Elicit Strong Anti-Human Immunodeficiency Virus CD8+ and CD4+ T-Cell Responses from Chronically Infected Individuals.
J. Engelmayer, M. Larsson, A. Lee, M. Lee, W. I. Cox, R. M. Steinman, and N. Bhardwaj (2001)
J. Virol. 75, 2142-2153
   Abstract »    Full Text »
Sensitive Genetic Screen for Protease Activity Based on a Cyclic AMP Signaling Cascade in Escherichia coli.
N. Dautin, G. Karimova, A. Ullmann, and D. Ladant (2000)
J. Bacteriol. 182, 7060-7066
   Abstract »    Full Text »
Production of resistant HIV mutants during antiretroviral therapy.
R. M. Ribeiro and S. Bonhoeffer (2000)
PNAS 97, 7681-7686
   Abstract »    Full Text »    PDF »
A Bacteriophage Lambda-Based Genetic Screen for Characterization of the Activity and Phenotype of the Human Immunodeficiency Virus Type 1 Protease.
M.-A. Martínez, M. Cabana, M. Parera, A. Gutierrez, J. A. Esté, and B. Clotet (2000)
Antimicrob. Agents Chemother. 44, 1132-1139
   Abstract »    Full Text »
Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe: Results From the EuroSIDA Study.
R. Paredes, A. Mocroft, O. Kirk, A. Lazzarin, S. E. Barton, J. van Lunzen, T. L. Katzenstein, F. Antunes, J. D. Lundgren, B. Clotet, et al. (2000)
Arch Intern Med 160, 1123-1132
   Abstract »    Full Text »    PDF »
Monitoring patients with HIV disease.
M. Helbert and J. Breuer (2000)
J. Clin. Pathol. 53, 266-272
   Full Text »    PDF »
High-Level Resistance to 3'-Azido-3'-Deoxythimidine due to a Deletion in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1.
T. Imamichi, T. Sinha, H. Imamichi, Y.-M. Zhang, J. A. Metcalf, J. Falloon, and H. C. Lane (2000)
J. Virol. 74, 1023-1028
   Abstract »    Full Text »
AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy: The Swiss HIV Cohort Study.
B. Ledergerber, M. Egger, V. Erard, R. Weber, B. Hirschel, H. Furrer, M. Battegay, P. Vernazza, E. Bernasconi, M. Opravil, et al. (1999)
JAMA 282, 2220-2226
   Abstract »    Full Text »    PDF »
How an Inhibitor of the HIV-I Protease Modulates Proteasome Activity.
G. Schmidtke, H.-G. Holzhutter, M. Bogyo, N. Kairies, M. Groll, R. de Giuli, S. Emch, and M. Groettrup (1999)
J. Biol. Chem. 274, 35734-35740
   Abstract »    Full Text »    PDF »
Primary HIV-1 Resistance: A New Phase in the Epidemic?.
R. J. Pomerantz (1999)
JAMA 282, 1177-1179
   Full Text »    PDF »
Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase.
R. Schuurman, L. Demeter, P. Reichelderfer, J. Tijnagel, T. de Groot, and C. Boucher (1999)
J. Clin. Microbiol. 37, 2291-2296
   Abstract »    Full Text »
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.
P. Andre, M. Groettrup, P. Klenerman, R. de Giuli, B. L. Booth Jr., V. Cerundolo, M. Bonneville, F. Jotereau, R. M. Zinkernagel, and V. Lotteau (1998)
PNAS 95, 13120-13124
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)